| 0.7496 -0.025 (-3.16%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.09 | 1-year : | 1.27 |
| Resists | First : | 0.93 | Second : | 1.09 |
| Pivot price | 0.75  |
|||
| Supports | First : | 0.68 | Second : | 0.57 |
| MAs | MA(5) : | 0.74  |
MA(20) : | 0.77 |
| MA(100) : | 0.99 |
MA(250) : | 1.31 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.6 |
D(3) : | 33.9 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 4.11 | Low : | 0.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GELS ] has closed above bottom band by 43.0%. Bollinger Bands are 59.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.77 - 0.77 | 0.77 - 0.78 |
| Low: | 0.72 - 0.73 | 0.73 - 0.73 |
| Close: | 0.74 - 0.75 | 0.75 - 0.76 |
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.
Sat, 28 Feb 2026
AUTL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Fri, 13 Feb 2026
AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI
Wed, 11 Feb 2026
New gel nutraceuticals to be made in U.S. under Gelteq deal - Stock Titan
Tue, 13 Jan 2026
Gel-based medicinal cannabis boosts CBD uptake 22%+ in early tests - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 5.46e+006 (%) |
| Held by Institutions | 47.5 (%) |
| Shares Short | 39 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.84e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 969.4 % |
| Return on Equity (ttm) | -15 % |
| Qtrly Rev. Growth | 413130 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 130040 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|